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Abstract
Background: Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of
severe rash or liver enzyme elevation (LEE) in HIV+ women.
Methodology: AE rates following ART initiation were retrospectively assessed in a multi-site cohort of 612 women.
Predictors of onset of rash or LEE were determined using univariate and multivariate analyses.
Principal Findings: Of 612 subjects, 152 (24.8%) initiated NVP-based regimens with 86 (56.6%) pregnant; 460 (75.2%)
initiated non-NVP regimens with 67 (14.6%) pregnant.
LEE: No significant difference was found between regimens in the development of new grade $2 LEE (p=0.885).
Multivariate logistic regression demonstrated an increased likelihood of LEE with HCV co-infection (OR 2.502, 95% CI: 1.04 to
6, p=0.040); pregnancy, NVP-based regimen, and baseline CD4 .250 cells/mm
3 were not associated with this toxicity.
Rash: NVP initiation was associated with rash after controlling for CD4 and pregnancy (OR 2.78; 95%CI: 1.14–6.76), as was
baseline CD4 .250 cells/mm
3 when controlling for pregnancy and type of regimen (OR 2.68; 95% CI: 1.19–6.02 p=0.017).
Conclusions: CD4 at initiation of therapy was a predictor of rash but not LEE with NVP use in HIV+ women. Pregnancy was
not an independent risk factor for the development of AEs assessed. The findings from this study have significant
implications for women of child-bearing age initiating NVP-based ART particularly in resource limited settings. This study
sheds more confidence on the lack of LEE risk and the need to monitor rash with the use of this medication.
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Introduction
The introduction of antiretroviral therapy (ART) has changed
HIV management from that of a uniformly fatal disease to that of
a chronic disease. Despite significant advances in HIV therapy,
ART-associated toxicities remain an important factor in the
treatment of HIV-infected persons. ART options, including for
pregnant women, are limited particularly in resource-limited
settings (RLS) and many countries rely on the use of nevirapine
(NVP). Adverse events characterized by liver and skin toxicities,
usually occurring within the first 18 weeks of treatment, have been
associated with the use of NVP [1–4]. Investigators have reported
these toxicities more frequently in women with higher baseline
CD4 counts (.250 cells/mm
3) [5]; in pregnancy [6]; and in the
presence of pre-existing liver disease (i.e. hepatitis C) [7].
However, it has not been confirmed that pregnancy increases
the risk of liver enzyme elevations (LEE) or rash in women
receiving NVP or other ART [8–10].
Due to the inability to systematically identify severe but non-
fatal toxicities associated with ART in pregnant patients outside of
clinical trials, the true incidence of adverse events associated with
NVP use in pregnancy is unknown [11]. This knowledge is critical
for facilitating the decision-making process of the clinician in
selecting optimal ART agents for use in pregnant patients.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12617Utilizing standardized data collected from three large HIV
clinics serving HIV-infected women, we sought to assess the
prevalence and the predictors of developing LEE and rash
associated with NVP as compared to non-NVP regimen use in
pregnant and non-pregnant women.
Methods
Study Design
Three university-based clinics with large prenatal patient
populations participated in a multi-center retrospective cohort
study: Drexel University College of Medicine, Philadelphia, PA;
Temple University, Philadelphia, PA; and the University of
Alabama at Birmingham, Birmingham, AL. This study was
approved by the institutional review board at each institution. A
database search identified all female patients on ART between
January 1999 and August 2005. Women 18–55 years old who
initiated a new ART regimen during that time period and had at
least one follow-up medical visit within 12 weeks of initiation, or
within 12 weeks of their first prenatal care visit, were eligible for
study entry. Eligible subjects could not be on ART at the start of
the study period. Women who became pregnant while on an ART
regimen were excluded. Thus both ART-naı ¨ve and ART-
experienced women were eligible, but only those women who
were not on ART at the entry into the study were included.
Women must have been followed for at least 12 weeks and up to
18 weeks after the initiation of a new ART regimen. Women who
initiated ART during the prenatal period and thus had any
exposure to ART during pregnancy were included in the
pregnancy group. Women who delivered during the 12–18 week
period were followed throughout the study time frame into the
postpartum period. Only the initial regimen that was started in this
time frame was included for analysis. Only the first pregnancy was
included in the analysis for women with more than one pregnancy
during the study period.
Data were checked for inter-rater reliability and entered into a
central database. Only charts that had clear documentation of
client visits and assessment of side effect profile during the study
period were included.
Demographic and medical information included: age, race/
ethnicity, HIV transmission risk, HIV disease stage, ART
regimens used during the study period, history of drug/alcohol
use, liver function tests (LFT), nadir (lowest CD4 count recorded)
and baseline CD4 count (result obtained at therapy initiation) as
well as CD4%, HIV RNA measures within 4 weeks prior to the
initiation of ART and throughout the study period, hepatitis C
virus (HCV) status, presence of AE symptomatology, medication
allergy, or intolerance.
Study Definitions
Baseline lab values were defined as measurements taken up to
28 days before regimen initiation. Abnormal alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) values and
rash were graded for severity according to the Toxicity Tables of
the Division of Acquired Immunodeficiency Syndrome (DAIDS)
[12]. Subjects were defined as having LEE if they had 1) at least
one episode of new grade $2 elevation in ALT/AST after one
week (considered baseline) and within 18 weeks of ART initiation,
or 2) for patients who entered with baseline grade $2 elevation, at
least one episode of elevation that was greater than their baseline
value after one week and within 18 weeks of ART initiation.
Patients who had a grade 4 LEE at baseline or had a rash at the
time of regimen initiation were excluded. Due to the paucity of
hepatitis C virus (HCV) viral load results available in the medical
record, a positive HCV serology was considered synonymous with
active hepatitis C infection for the purposes of this study. Patients
whose rash was caused by other reasons, such as pruritic urticarial
papules and plaques of pregnancy, herpes zoster, allergic
dermatitis, etc., were excluded from entry into the study.
Statistical Analysis
The sample size had $80% power to detect a difference in
adverse events, of 10% vs. 3%, for NVP vs. non-NVP. Statistical
analyses were performed using SPSS Version 15. Chi-square tests
for dichotomous outcomes were used for regimen comparisons.
Analyses were stratified by baseline CD4 cell count (#250 cells/
mm
3 vs. .250 cells/mm
3) and pregnancy status. Unpaired t-tests
or Mann Whitney U tests were used for continuous variables.
Results were considered statistically significant at p#0.05.
Univariate analyses were performed to test the difference in
adverse event rates between NVP and non-NVP regimens. The
results are expressed as relative risks. Multivariate logistic
regression analysis was used to assess possible confounding factors
such as pregnancy, baseline CD4 count (#250 cells/mm
3 vs.
.250 cells/mm
3), and presence of HCV. Odds ratios (OR) and
95% confidence intervals (CI) are provided. Because of the small
number of events and specific research questions, no correction for
multiple comparisons was employed.
Results
Study Sample
Of the 612 subjects included in the analyses, 152 (24.8%)
initiated NVP-containing ART, 86 (56.6%) of whom were
pregnant. Among the remaining 460 (75.2%) patients who
initiated non-NVP-containing regimens, 67 (14.6%) patients were
pregnant. Thirty-nine women became pregnant after initiating
ART and were excluded. Among the pregnant women included
66 started ART at the initiation of the study with baseline CD4
counts below 350 cells/mm
3 (37 [56.1%] on a NVP-based
regimen) and received ART based on their current stage of HIV
disease. The remaining 87 women started ART at baseline CD4
counts above 350 cells/mm
3 (49 [56.3%] on a NVP-based
regimen) and initiated ART for the prevention of mother to child
transmission (PMTCT). Based on the exclusion criteria [see Study
Definitions], 599 women were included in the liver analysis and
526 in the rash analysis. [Figures 1 and 2].
The baseline demographic and clinical characteristics are
shown in Table 1: 72.4% (n=443) patients were of black race/
ethnicity, 18.1% (n=111) were of white non-Hispanic race/
ethnicity, 8.7% (n=53) were of Hispanic race/ethnicity and 0.3%
(n=2) were multiracial. Three subjects were missing race/ethnic
information. The racial/ethnic distribution did not differ between
the treatment groups (p=0.191). Of those with known transmis-
sion risk, heterosexual mode of transmission was the primary risk
factor in both groups (83.6% for NVP and 85.4% for non-NVP,
p=0.538). NVP recipients had higher baseline CD4 counts, and
lower HIV-1 RNA viral loads (both p values ,0.001). There was
no significant difference in co-infection with HCV (22.0% NVP vs.
17.9% non-NVP, p=0.328) when stratified by type of regimen use
[Table 1].
Patients on NVP-based regimens were significantly younger
(mean: 32.8; SD: 68.9 years) than those on non-NVP-based
regimens (mean: 37.3; SD: 67.9 years, p,0.001). [Table 1]
However, when controlling for pregnancy there were minimal
differences between groups. Specifically, in the non-pregnant group
the mean (SD) ages for those receiving NVP-based regimens and
non-NVP-based regimens were 38.8 (8.5) years and 38.6 (7.3) years,
NVP Pregnant/Nonpregnant Women
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non-NVP were 28.0 (5.5) and 29.4 (6.3), respectively. Pregnant
womenweremore likelytobeonNVP(86[56.2%]vsnon-pregnant
66 [14.4%]p,0.001), had higher CD4counts(113 [74.3%] vs non-
pregnant 210 [45.9.4%] p,0.001), and were of younger age (28.62
vs non-pregnant 38.68 p,0.001). Pregnant women were also less
likely to have Hepatitis C (10 [9.2%] vs non-pregnant 83 [21.5%]
p=0.004). [Table 2] LFTs were assessed with equal frequency in
the pregnant cohort and the non-pregnant cohorts (p=0.388) as
well as amongst those pregnant and not pregnant receiving NVP
(p=0.301) and non-NVP-based regimens (p=0.712).
Among those receiving NVP, 20.8% were ART experienced
and 70.0% were ART naı ¨ve and there were no significant
differences in the demographics of ART experienced versus ART
naı ¨ve women receiving NVP. Of those who were on NVP and
pregnant, 43.0% were experienced and 53.0% were naı ¨ve and of
those who were not pregnant, 57.0% were experienced and 47.0%
were naive (p=0.33). Amongst ART experienced women, 40.0%
Figure 1. Subjects included in hepatic adverse events analysis.
doi:10.1371/journal.pone.0012617.g001
Figure 2. Subjects included in rash analysis.
doi:10.1371/journal.pone.0012617.g002
NVP Pregnant/Nonpregnant Women
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(p=0.35).
Of those women on non-NVP based therapy, 18.3% (n=83)
were on nucleoside-based therapy only, though none received
zidovudine monotherapy. Two hundred thirty four (50.9%)
women were on protease inhibitors: 25.0% (n=58) on lopina-
vir/ritonavir, 3.0% (n=14) on amprenavir, 37.0% (n=87) on
nelfinavir, 1.5% (n=7) on saquinavir, 5.0% (n=23) on indinavir,
and 9.8% (n=45) on boosted or unboosted atazanavir. There
were 143 (31.1%) women were on efavirenz, two of whom were
pregnant.
Pregnant women on NVP started ART at a mean of 19.1 weeks
gestation (median: 18 weeks, range 8–32 weeks). Women on non-
NVP regimens started ART at a mean of 18.7 weeks gestation
(median 16 weeks – range 3–38 weeks, p=0.693). If women were
started on ART during the prenatal period and thus had any
exposure to ART during pregnancy, they were included in the
pregnancy group. If they delivered during the 12–18 week period,
we continued to follow them throughout the study time frame into
the postpartum period.
Adverse Events: The majority of liver and skin AE in both
regimen groups occurred within 6 weeks of initiating ART: 7/
9(77.8%) $2 LEE on NVP, 16/26 (61.5%) $2 LEE non-NVP
(p=0.63 by continuity-corrected chi-square); 8/11 (72.7%) skin
AE on NVP and 12/19 (63.2%) skin AE on non-NVP (p=0.893
by continuity-corrected chi-square).
Hepatic: In total 38 subjects experienced LEE of grade $2a t
baseline or during the 12–18 week follow-up period; 11 were
excluded per exclusion criteria. There were no significant
differences in LEE by regimen group: NVP 6/140 (4.3%) vs.
non-NVP 21/459 (4.6%) (p=0.885). [Table 3] Among women
experiencing LEE, 7 developed grade $3 LEE, with no significant
differences between NVP (n=2, 1.4%) and non-NVP (n=5,
1.1%; p=0.668). Those on NVP with grade 3 LEE were pregnant
with baseline CD4 .250 cells/mm
3 (n=2) and those on non-NVP
were not pregnant with baseline CD4 #250 cells/mm
3 (n=5).
[Figure 1]
There were no cases with initial grade $2 LEE at baseline who
subsequently had higher liver elevations during follow-up. There
were two women who had baseline liver elevations of grade 3 who
did not progress and thus were not counted as LEE due to ART.
In the univariate analysis, a non-significant trend was noted for an
increased relative risk for the development of LEE in NVP users
with baseline CD4 counts .250 cells/mm
3 (p=0.054 two-tailed).
Patients on non-NVP regimes experienced a significant increase in
LEE when the baseline HIV-1 RNA VL was greater than 100,000
copies/ml (p=0.04), an association that was not noted in subjects
on NVP-regimens.
Women who were co-infected with HCV were more likely than
those without HCV to develop grade $2 LEE regardless of
regimen group: 9.9% (9/91) of HCV co-infected patients vs. 3.8%
(15/394) of HCV negative patients (p=0.03). However, there was
Table 1. Demographic and Clinical Characteristics at Enrollment for 612 HIV+ Women stratified by Antiretroviral Regimen.
Subjects on NVP-based
regimen (n=152)
Subjects on non-NVP-based
regimen (n=460) P-value
Age (mean; years) 32.8 37.3 ,0.001
Pregnancy 86 (56.6%) 67 (14.6%) ,0.001
Race N=152 N=457 0.191
Black 112 (73.7%) 331 (72.4%)
White, non-Hispanic 31 (20.4%) 80 (17.5%)
Hispanic 9 (5.9%) 44 (9.6%)
Multiracial 0 2 (0.4%)
Mode of transmission N=140 N=398 0.538
IV drug use 22 (15.7%) 54 (13.6%)
Unprotected sex w/male 117 (83.6%) 340 (85.4%)
Other risks 1 (0.7%) 4 (1.0%)
Baseline CD4 N=152 N=459 ,0.001
Median (cells/mm
3) 352 246
#250 cells/mm
3 50 (32.9%) 237 (51.6%)
.250 cells/mm
3 102 (67.1%) 222 (48.4%)
Baseline Viral Load (HIV RNA copies/ml) N=146 N=453 ,0.001
,400 28 (19.2%) 47 (10.4%)
400–9,999 54 (37.0%) 110 (24.3%)
10,000–49,999 33 (22.6%) 100 (22.1%)
50,000–99,999 13 (8.9%) 66 (14.6%)
$100,000 18 (12.3%) 130 (28.7%)
Hep C serology N=109 N=386
Positive Hep C serology 24 (22.0%) 69 (17.9%) 0.328
Negative Hep C serology 85 (78.0%) 317 (82.1%)
Percentages may not equal 100 due to rounding.
doi:10.1371/journal.pone.0012617.t001
NVP Pregnant/Nonpregnant Women
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Pregnant (n=152) Not Pregnant (n=460) P-value
Age (mean; years) 28.62 38.68 ,0.001
Type of Regimen N=153 N=459 ,0.001
NVP 86 (56.2%) 66 (14.4%)
Non-NVP 67 (43.8% 393 (85.6%)
Race N=153 N=456 0.338
Black 117 (76.5%) 326 (71.5%)
White, non-Hispanic 21 (13.7%) 90 (19.7%)
Hispanic 14 (9.2%) 39 (8.6%)
Multiracial 1 (0.7%) 1 (0.2%)
Mode of transmission N=153 N=459 ,0.001
IV drug use 9 (5.9%) 67 (14.6%)
Unprotected sex w/male 141 (92.2%) 316 (68.8%)
Other risks 3 (1.9%) 76 (16.6%)
Baseline CD4 N=152 N=458 ,0.001
Median (cells/mm
3) 401 236
#250 cells/mm
3 39 (25.7%) 248 (54.1%)
.250 cells/mm
3 113 (74.3%) 210 (45.9.4%)
Baseline Viral Load (HIV RNA copies/ml) N=148 N=451 ,0.001
,400 19 (12.8%) 56 (12.4%)
400–9,999 76 (51.4%) 88 (19.5%)
10,000–49,999 35 (23.6%) 98 (21.7%)
50,000–99,999 13 (8.8%) 66 (14.6%)
$100,000 5 (3.4%) 143 (31.7%)
Hep C serology N=109 N=386
Positive Hep C serology 10 (9.2%) 83 (21.5%) 0.004
Negative Hep C serology 99 (90.8%) 303 (78.5%)
Percentages may not equal 100 due to rounding.
doi:10.1371/journal.pone.0012617.t002
Table 3. Clinical Characteristics of HIV+ women developing new onset grade $2 LEE (n=27).
Characteristic NVP-Regimen (n=140) non-NVP Regimen (n=459) Relative risk (95% CI) P*-value
All 6/140(4.3%) 21/459(4.6%) 0.94 (0.38–2.28) 0.885
Baseline (n=599)
CD4#250 cells/mm
3 0/48 (0%) 16/237(6.8%) 0 (NA) 0.131
CD4.250 cells/mm
3 6/92 (6.5%) 5/222 (2.3%) 2.9 (0.91–9.25) 0.122(a)
Pregnant 2/79 (2.5%) 0/67 (0%) 0.551
CD4#250 cells/mm
3 0/23 (0%) 0/16 (0%) NA NA
CD4.250 cells/mm
3 2/56 (3.6%) 0/51 (0%) NA 0.517
Non-pregnant 4/61(6.6%) 21/392(5.4%) 0.936
CD4#250 cells/mm
3 0/25 (0%) 16/221(7.2%) 0 (NA) 0.335
CD4.250 cells/mm
3 4/36(11.1%) 5/171 (2.9%) 3.8 (1.07–13.46) 0.082
HCV** (n=485) 6/100(6.0%) 18/385(4.7%) 1.28 (0.52–3.15) 0.810
HCV Positive 2/22 (9.0%) 7/69 (10.1%) 0.9 (0.2–4.0) 1.000
HCV Negative 4/78 (5.1%) 11/316(3.5%) 1.47 (0.48–4.5) 0.737
*All p values are continuity-corrected chi-square, 2-tailed.
**HCV denominators are lower because this information was not available for all subjects.
(a) p=0.054 two-tailed for the comparison of NVP related relative risks in high and low baseline CD4 count groups.
NA: Risk estimates are not reported since adverse events were not observed for both treatment categories.
doi:10.1371/journal.pone.0012617.t003
NVP Pregnant/Nonpregnant Women
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vs. HCV patients on non-NVP (10.1%, 7/69) (p=1.0). In
Hepatitis C negative patients, the relative risk for NVP verses
non-NVP use and the development of grade .2 LEE in those with
baseline CD4 .250 cells/mm
3 was 5.81 (95%, CI: 1.1 to 30.8,
p=0.039 by Fisher’s Exact Test). In contrast, no one in the NVP
group with baseline CD4 #250 cells/mm
3 developed LEE
(p=0.61 by Fisher’s Exact Test, data not shown).
Multivariate logistic regression performed to identify indepen-
dent predictors of new grade $2 LEE demonstrated an increased
likelihood of hepatic AE in those with HCV co-infection (OR
2.502; 95% CI: 1.04 to 6, p=0.040). Pregnancy status (OR 0.178;
CI: 0.022–1.43, p=0.104), NVP use (OR 1.62; CI: 0.55–4.76,
p=0.38) and baseline CD4 count .250 cells/mm
3 (OR 0.62; CI:
0.25–1.50, p=0.29) were not independently associated with the
development of LEE.
Adverse Events-Rash: In total, 114/526 (21.7%) women
developed a new rash (Grades 1–4) after therapy initiation with 30
(5.7%) women developing a new grade $2 rash during the study
period. One non-pregnant subject on NVP was diagnosed with
Stevens-Johnson syndrome 22 days after initiation of treatment;
CD4 count at therapy initiation was 420 cells/mm
3. The patient
was hospitalized and had complete resolution of rash within 12
days of discontinuing ART. [Figure 2]
No difference in the frequency of new rash was seen between
regimen groups. However, there was a higher incidence of severe
rashes in the NVP regimen group vs. non-NVP group (p=0.002):
for grade 3 rash 2/127 (1.6%) on NVP-based regimens vs. 0/399
on non-NVP-based regimens; for grade 4 rash 2/127 (1.6%) on
NVP vs. 0/399 on non-NVP. There was a non-significant trend
towards a higher frequency of grade $2 rashes: 11/127 (8.7%)
among those who initiated NVP-based regimens vs. 19/399 (4.8%)
on non-NVP regimens (p=0.099). [Table 3]
Furthermore, NVP-based regimens were significantly associated
with the diagnosis of grade $2 rash in subjects with baseline
CD4 .250 cells/mm
3 (p=0.001). A comparison of the relative
risks for development of rash among women on NVP-based
regimen was significantly different between the two CD4 sub-
groups (p=0.005), indicating an interaction between treatment
regimen and CD4 count. There was a trend of increased risk for
the development of grade $2 rashes in the NVP treatment group
among pregnant women (p=0.054) but not among non-pregnant
women (p=0.476).
Stratifying women by CD4 count at baseline, NVP exposure
was associated with the development of grade $2 rashes in
pregnant patients with baseline CD4 count .250 cells/mm
3
(p=0.042); a similar trend could be observed in non-pregnant
patients (p=0.058). No association with regimen use was seen with
baseline CD4 count #250 cells/mm
3.
Using multivariate logistic regression modeling controlling for
type of regimen, pregnancy status and baseline CD4 count,
women were more likely to develop a grade $2 rash if they
initiated an NVP-based regimen (OR 2.78; 95% CI: 1.14–6.76,
p=0.024) or had baseline CD4 counts$250 cells/mm
3 (OR 2.68;
95% CI: 1.19–6.02 p=0.017). Pregnancy status was not an
independent predictor for the development of a grade $2 rash
(OR 0.46 95% CI: 0.15–1.4p=0.165). However, pregnant women
were more likely to be on NVP and more likely to start therapy at
higher CD4 counts. [Table 4]
A secondary analysis was performed to evaluate the AE patterns
for CD4 percentage below and above 20%. During pregnancy
there is a lowering of absolute CD4 count due to hemo-dilution
and CD4 percentage measurements may be more reliable [13].
Our results demonstrated a non-significant trend in increased risk
of LEE in women on NVP with a CD4 percentage above 20% (3/
83, 3.6%) when compared to women on non-NVP-based regimens
(1/188, 0.5%) (p=0.164 RR=6.8 (0.72–64.4). The risk of rash in
those on NVP was increased five-fold among those with CD4
percent .20%, though this finding did not reach statistical
significance (NVP - 4/79 (5.1%), non-NVP-2/178 (1.1%)
p=0.138, RR=4.51 (0.84–24.1)). NVP use was also associated
with an increased risk of rash in the low CD4 percentage group
though to a lesser extent when compared to the group of
individuals with higher CD4 percent values (NVP - 5/43 (11.6%),
Non-NVP -17/211 (8.1%) p=0.645 RR=1.44 (0.56–3.7).
Discussion
This large multi-center, retrospective cohort study of 612
pregnant and non-pregnant women on NVP and non-NVP ART
regimens assessed the cumulative incidence of hepatic and rash-
related adverse events over the first 18 weeks post-ART initiation.
The strengths of this study include the multi-center nature of the
study, the significant sample size and the use of a large non-
pregnant comparison group, a group that has been missing from
other studies evaluating the relationship of AEs and ART during
pregnancy. The majority of liver and skin AEs in both regimen
groups in the current study occurred within 6 weeks of initiating
ART. There were no significant differences in the overall
percentage of patients developing LEE between regimen groups.
We did not find a statistically significant association between
baseline CD4 cell count above 250 cells/mm
3 and the risk of
hepatotoxicity in patients taking NVP in univariate and multivar-
iate analyses. Though a non-significant trend towards an increased
risk of LEE in the higher CD4 count group was noted in the
univariate analysis, no such association was noted in the
multivariate analysis. NVP use in women with baseline CD4
counts #250 cells/mm
3, including pregnant women, resulted in a
hepatic safety profile similar to women treated with non-NVP
regimens.
In comparison, both pregnant and non-pregnant women on
NVP with a baseline CD4 count .250 cells/mm
3 had a
significantly increased rate of grade $2 rash compared to women
on non-NVP regimens with CD4 count .250 cells/mm
3. NVP
use was predictive of rash when controlling for CD4 count at
regimen initiation and pregnancy.
The lack of association of an effect of CD4 count on LEE is
consistent with recent studies [9,10,14]. Ouyang reported on 1358
women with ART exposure during pregnancy and found no
association between CD4 cell count above 250 cells/mm
3 and risk
of hepatotoxicity in patients taking NVP [9]. Our findings are also
consistent with a large review on NVP and hepatotoxicity which
also failed to demonstrate an association [14]. However, the results
from this study are in contrast to prior published studies in which a
greater proportion of women on NVP with CD4 counts .250
cells/mm
3 had moderate to severe side effects as compared to
those with CD4 counts #250 cells/mm
3 [6]. Bersoff-Matcha
found that both a higher CD4 at initiation of NVP therapy and a
higher nadir CD4 count were strongly associated with the
development of severe rash and discontinuation of therapy [15].
The risk of NVP–induced hepatitis was found to be increased 12-
fold in women with greater than 250 CD4 cells/mm
3 [16]. In a
summary analysis of 17 clinical trials using NVP, the risk ratio was
9.8 in women with rash-associated hepatic events with CD4 count
.250 cells/mm
3 as compared to those with lower CD4 counts.
[17].
In this study, pregnancy was not an independent risk factor for
the development of LEE or rash. In contrast, a recent study of
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significantly associated with risk of LEE, and that pregnancy was a
risk factor for LEE [10].
Hepatitis C co-infection was independently associated with the
development of LEE in this cohort. This finding is consistent with
previous studies that have examined the association of HCV with
hepatoxicity in patients on ART. Co-infected patients in these
studies were found to have a significantly greater risk of
experiencing hepatic events [18–20]. Vogel and colleagues studied
the impact of chronic viral hepatitis on the pharmacokinetics of
NVP. They found that other factors such as accumulating NVP
drug levels may be responsible for an increased risk of liver
damage in HIV/HCV co- infected patients [21]. Rivero and
colleagues found that HCV co-infection increased by two to seven
fold the risk of developing LEE .2 in patients treated with non-
nucleoside reverse transcriptase inhibitors [22]. Bonnett showed
that patients with HCV and/or HBV co-infection who received
NVP containing regimens had a 45% increase in hepatotoxicity at
month 12 of follow-up when compared to patients without co-
infection [23].
In our study, NVP use was predictive of rash even when
controlling for CD4 and pregnancy. The 2NN Trial reported
grade $3 rash occurrence in 3.4% of patients taking NVP twice
daily [24]. Aggregate data from 1,752 patients who participated in
33 NVP clinical trials revealed a rash rate of 17.0%, the majority
of which occurred within 6 weeks of NVP initiation: 6.0%
discontinued NVP due to rash, and 0.5% developed Steven-
Johnson syndrome [25]. Pollard reviewed prospective clinical trials
with NVP and found an incidence of 0.3% SJS [26].
Recent studies have demonstrated that virologically suppressed
patients switching to NVP do not show a higher risk of
hepatotoxicity or rash dependent on CD4 counts [4]. The
ATHENA cohort also suggested that the incidence of hypersen-
sitivity reaction associated with NVP in patients with undetectable
HIV RNA load at the start of NVP is lower in patients with prior
treatment experience than those who are treatment naı ¨ve. While
the importance of VL as a predictor for rash with NVP remains
debatable, the current study has demonstrated that patients on
non-NVP regimes had a significant increase in liver enzyme
elevations at baseline HIV-1 RNA VL .100,000 copies/ml, a
finding that was not seen in subjects on NVP-containing regimens
(p=0.04).
During pregnancy there is a lowering of absolute CD4 count
due to hemo-dilution. The stability of CD4 percentage measure-
ments in comparison to absolute CD4 counts between prepartum
and postpartum periods have been confirmed [13]. Similar to
absolute CD4 count, CD4 .20% in this study demonstrated a
non-significant trend in the increase of LEE and rash-related
events associated with the use of NVP.
Our study has limitations that should be considered. There was
an overrepresentation of pregnant women who were using NVP,
had higher CD4 counts, and were of younger age. These women
were also less likely to have Hepatitis C. It could be hypothesized
that the reason why LEE and rash were seen more frequently in
women with higher baseline CD4 counts on NVP-based regimens
was due to these confounding factors. However, pregnancy was
not an independent predictor of LEE or rash. Since women in the
United States who are HIV-infected and pregnant are many times
diagnosed earlier in their disease process during pregnancy
through HIV screening programs, and are younger due to the
childbearing years, this overrepresentation is hard to avoid [27].
The limitation of a retrospective study resulted in the reliance
on chart documentation to distinguish drug induced hepatotox-
icity from hepatotoxicity due to other causes. Women who are
pregnant have an increased rate of LEE due to conditions that are
unique to pregnancy [10]. In addition due to insufficient reporting
in clinic records, alcohol use, drug use, and Hepatitis B were not
evaluated as confounding factors. The fact that a positive hepatitis
serologic result was used as a surrogate for chronic active HCV
infection may have resulted in an attenuation of the association
between HCV and LEE as several of the women who were HCV
antibody positive may have cleared their infection. Finally, AST/
ALT values may not be specific enough markers for liver injury. It
is known that only a small proportion of those with LEE will
eventually develop fulminant hepatitis or acute liver failure and
that LEE often resolve without any intervention. Many instances
of drug induced liver disease are unpredictable and asymptomatic.
The results from this study should be considered in assessing the
recommendations for use of NVP in all women, but particularly
for women of childbearing age in resource limited settings (RLS).
The 2009 World Health Organization (WHO) now recommends
starting lifelong ART for all pregnant women with a CD4 count at
or below 350 cells/mm
3 regardless of symptoms. ART is
recommended to be continued in all pregnant women during
Table 4. Clinical Characteristics of HIV+ women developing new onset grade $2 rash (n=30).
Characteristic NVP-Regimen (n=127) non-NVP Regimen (n=399) Relative Risk (95% CI) P*-value
All 11/127 (8.7%) 19/399 (4.8%) 1.82 (0.89–3.72) 0.099
Baseline (n=526)
CD4#250 cells/mm
3 2/39 (5.1%) 17/189 (8.9%) 0.57 (0.14–2.37) 0.633 (a)
CD4.250 cells/mm
3 9/87 (10.3%) 2/209 (1.0%) 10.74 (2.37–48.7) ,0.001
Pregnant 6/73 (8.2%) 0/64 (0%) NA 0.054
CD4#250 cells/mm
3 0/20 (0%) 0/15 (0%) NA NA
CD4.250 cells/mm
3 6/52 (11.3%) 0/49 (0%) NA 0.042
Non-pregnant 5/54 (9.3%) 19/355 (5.7%) 1.63 (0.64–4.19) 0.476
CD4#250 cells/mm
3 2/19 (10.5%) 17/174 (9.8%) 1.08 (0.27–4.31) 1.000
CD4.250 cells/mm
3 3/35 (8.6%) 2/160 (1.2%) 6.9 (1.20–39.77) 0.058
*All p values are continuity-corrected chi-square, 2-tailed.
(a) p=0.005 two-tailed for the comparison of NVP relative risks in high and low CD4 count groups.
NA: Risk estimates are not reported since adverse events were not observed for both treatment categories.
doi:10.1371/journal.pone.0012617.t004
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These guideline changes mean that more pregnant women will be
initiating NVP-based regimens as part of first-line ART therapy in
RLS [28]. In comparison to other studies in RLS where an
association between high CD4 counts and LEE and rash have
been reported, this study supports increased confidence on the use
of NVP in similar populations as pregnancy status, NVP use, and
baseline CD4 count $250 cells/mm
3 were not independent
predictors for the development of LEE [28,29]. In addition, the
DART study showed that routine laboratory monitoring for toxic
effects in HIV patients receiving ART had no benefit in RLS [30].
Our study confirms that while clinical monitoring would detect the
increased risk of rash seen with NVP use in women with higher
CD4 cell counts, the risk of LEEs described may not result in
significant hepatotoxicity to necessitate lab testing. As rash and
hepatic events occurred more frequently in the first 6 weeks of
NVP initiation in this analysis, more diligent clinical monitoring is
recommended during this time frame.
Our study cohort is representative of the HIV epidemic in
women in U.S. women in terms of age, race, HIV transmission
risk and HCV status, and therefore contributes to the knowledge
needed to better characterize adverse events specific to this
population (7). This large cohort study provides additional
information for clinicians in assessing the risk of NVP-induced
liver and skin toxicity by taking into account the short latency
period and potential risk factors such as baseline CD4 counts and
HCV co-infection. All HCV co-infected women on NVP based
regimens should undergo close monitoring for LEE. Empiric use
of NVP in the absence of resources to determine baseline CD4
count and monitor liver enzyme levels continues to call for careful
consideration of the risks and benefits of NVP therapy. However,
with the significant increase in women of childbearing age
initiating NVP-based ART in RLS, where there is limited
laboratory capacity to monitor for LEE, this study provides
supportive evidence for the use of NVP in this population.
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